Robert Malenka Sells 736 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 736 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $18.15, for a total transaction of $13,358.40. Following the completion of the sale, the director owned 325,059 shares in the company, valued at $5,899,820.85. The trade was a 0.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Maplight Therapeutics Stock Performance

Shares of NASDAQ MPLT traded down $0.28 during midday trading on Tuesday, hitting $18.02. 97,940 shares of the company’s stock were exchanged, compared to its average volume of 185,529. Maplight Therapeutics, Inc. has a twelve month low of $12.24 and a twelve month high of $21.55. The stock has a market cap of $817.57 million and a price-to-earnings ratio of -0.48. The business’s 50 day moving average is $17.83.

Maplight Therapeutics (NASDAQ:MPLT) last announced its earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Ratings Changes

Several equities research analysts recently weighed in on MPLT shares. Weiss Ratings initiated coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. Morgan Stanley assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued an “overweight” rating and a $34.00 price objective for the company. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Stifel Nicolaus started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $28.00 target price for the company. Finally, Zacks Research raised Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.00.

Institutional Investors Weigh In On Maplight Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Strs Ohio bought a new stake in shares of Maplight Therapeutics during the 4th quarter worth $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Maplight Therapeutics during the fourth quarter valued at $70,000. New York State Common Retirement Fund acquired a new position in shares of Maplight Therapeutics in the 4th quarter valued at $93,000. MetLife Investment Management LLC purchased a new position in Maplight Therapeutics in the 4th quarter worth about $172,000. Finally, Walleye Capital LLC acquired a new stake in Maplight Therapeutics during the 4th quarter worth about $205,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.